Intrapulmonary administration of polynucleotide toll-like receptor 9 agonists for treating cancer of the lung
US9993495B2 · kind B2 · utility
7Cited by
2References
35Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 23, 2016 |
| Grant date | Jun 12, 2018 |
| Priority date | — |
| Expiry date | Oct 1, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/55511
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to methods for treating cancer by intrapulmonary administration of a polynucleotide Toll-like receptor 9 agonist. The methods of the present disclosure are suitable for treating primary cancer of the lung, as well as metastatic cancer to the lung and extra pulmonary cancers thereof. Additionally, the present disclosure provides polynucleotide Toll-like receptor 9 agonists with immune stimulatory and toxicity profiles suitable for intrapulmonary administration.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.